The 2026 approval of Tauklarify gave doctors a second tau PET tracer for Alzheimer's evaluation, used alongside amyloid PET rather than replacing it. For families facing symptoms before age 65, that means earlier tangle detection and clearer staging when the diagnosis is uncertain.
Tauklarify (florquinitau F 18, also called MK-6240) is an injected tracer that lights up tau tangles on a brain PET scan. Amyloid PET lights up a different protein, amyloid plaques. The two scans answer different questions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from NIH — Use this primary source to verify the official guidance.
- Read the official notice from Lantheus — Use this primary source to verify the official announcement.
Table of Contents
- What does each scan show?
- What changed with the 2026 approval?
- Why does earlier tangle detection matter?
- What does this mean before age 65?
- What limits and next steps should families expect?
What does each scan show?
Amyloid PET detects early plaques using three approved tracers: florbetapir, flutemetamol, and florbetaben. A positive amyloid scan shows Alzheimer's biology is present. It does not by itself show how far symptoms have progressed.
Tau PET shows neurofibrillary tangles, twisted tau fibers inside brain cells. According to the NIH review shared in the evidence packet, tau burden tracks symptoms and staging more closely than amyloid (NIH review of amyloid and tau tracers). Doctors often use amyloid to confirm the disease process and tau to judge stage and fit with symptoms.
What changed with the 2026 approval?
Lantheus announced FDA approval of Tauklarify on Aug. 14, 2026 for brain PET in adults with cognitive impairment evaluated for Alzheimer's (Lantheus announcement of the FDA approval). It became the second approved tau tracer alongside Lilly's Tauvid, approved in 2020.
The approval rested on two studies in more than 500 participants whose scans were read independently as tau-positive or tau-negative. In practice, clinics now have a choice of tau tracers. According to the Society of Nuclear Medicine and Molecular Imaging, Tauklarify binds tau tangles to complement amyloid PET rather than replace it (SNMMI report on the new tau tracer). A patient may still need both scans: one for plaques, one for tangles.
Why does earlier tangle detection matter?
Tangles spread in a predictable pattern as memory and thinking worsen. A tracer that shows low levels of tangles can place a person earlier on that path. That timing shapes care plans, safety decisions, and treatment choices.
A first head-to-head study scanned the same people with both tau tracers. Reporting on the Lancet study found MK-6240 detected tangles earlier and staged disease more accurately than Tauvid. For younger adults with mild or confusing symptoms, that difference can reduce delay.
What does this mean before age 65?
Younger-onset means disease before age 65 and affects about 200,000 Americans. In this group, symptoms are often atypical, with language, vision, planning, or behavior changes rather than plain forgetfulness.
Biomarker confirmation is especially valuable when age alone points away from Alzheimer's. Joint 2025 Alzheimer's Association–SNMMI criteria rate amyloid and tau PET as appropriate when mild cognitive impairment or dementia occurs under age 65 with suspected Alzheimer's. Families can use that point in a referral conversation:.
- note symptom onset age and first domains affected
- bring examples of work, driving, or daily-task changes
- ask whether amyloid PET, tau PET, or both fit the question
- request a center that reads both scans for Alzheimer's evaluation
What limits and next steps should families expect?
Tauklarify is limited to Alzheimer's evaluation. Safety and effectiveness for non-Alzheimer tau diseases are unestablished, so it cannot sort every tau-related disorder. Rollout timing and commercial availability also remain undisclosed.
That makes the next step practical, not technical. Ask a memory clinic or neurologist whether the site offers tau PET, which tracer it uses, and whether results will be read as positive or negative for care planning. Bring a full medication list, prior MRI records, and a symptom timeline to that visit.
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
